Quick Answer
Moleculin Biotech, Inc. reported Research And Development Expense of $15.89 million for the year ending 2025.
- Moleculin Biotech, Inc. showed a decrease of -10.4% in Research And Development Expense from 2024 to 2025.
- This data is from Moleculin Biotech, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), Moleculin Biotech, Inc.'s Research And Development Expense has grown by 962.2%.
- Historical annual values: Fiscal year 2025: $15.89 million | Fiscal year 2024: $17.73 million | Fiscal year 2023: $19.49 million | Fiscal year 2022: $18.97 million | Fiscal year 2021: $14.42 million | Fiscal year 2020: $12.76 million | Fiscal year 2019: $11.01 million | Fiscal year 2018: $9.73 million | Fiscal year 2017: $4.55 million | Fiscal year 2016: $1.50 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: